These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18042326)

  • 21. Hypogonadism and metabolic syndrome: implications for testosterone therapy.
    Makhsida N; Shah J; Yan G; Fisch H; Shabsigh R
    J Urol; 2005 Sep; 174(3):827-34. PubMed ID: 16093964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone replacement therapy in men with type 2 diabetes mellitus and functional hypogonadism -an Integrated Diabetes and Endocrine Academy (IDEA) consensus guideline.
    Majumdar S; Mukherjee JJ; Ray S; Goswami S; Jude E; Biswas A; Hanumanthu A; John M; Sinha B; Ghoshal S; Kota S; Sharma SK; Jacob JJ
    Diabetes Metab Syndr; 2021; 15(4):102191. PubMed ID: 34245961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome.
    Jones TH
    J Diabetes; 2010 Sep; 2(3):146-56. PubMed ID: 20923480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of testosterone in type 2 diabetes and metabolic syndrome in men.
    Saad F
    Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):901-7. PubMed ID: 20126841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes.
    Corona G; Rastrelli G; Maggi M
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):557-79. PubMed ID: 24054931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone deficiency syndrome among males with type 2 diabetes mellitus in East Malaysia.
    Ahmad S; Jerampang P; Tohid H; Ali MF; Jamil TR; Kong CHC
    Nagoya J Med Sci; 2020 Nov; 82(4):613-621. PubMed ID: 33311792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypogonadotropic Hypogonadism in Men With Diabesity.
    Dhindsa S; Ghanim H; Batra M; Dandona P
    Diabetes Care; 2018 Jul; 41(7):1516-1525. PubMed ID: 29934480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relevant clinical and biological criteria for the diagnosis of androgen deficiency in the aging male (ADAM)].
    Seisen T; Rouprêt M; Gallais JL; Costa P
    Prog Urol; 2012 Jun; 22 Suppl 1():S21-6. PubMed ID: 22770497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy.
    Hassan J; Barkin J
    Can J Urol; 2016 Feb; 23(Suppl 1):20-30. PubMed ID: 26924592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypogonadism and metabolic syndrome: review and update.
    Berg WT; Miner M
    Curr Opin Endocrinol Diabetes Obes; 2020 Dec; 27(6):404-410. PubMed ID: 33044245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ; Doros G; Hammerer PG; Yassin AA
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men.
    Corona G; Bianchini S; Sforza A; Vignozzi L; Maggi M
    Hormones (Athens); 2015; 14(4):569-78. PubMed ID: 26732155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYTHS AND CONTROVERSIES IN HYPOGONADISM TREATMENT OF AGING MALES.
    Ungureanu MC; Costache II; Preda C; Mogoş V; Vulpoi C; Leuştean L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):325-33. PubMed ID: 26204632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men.
    Rao PM; Kelly DM; Jones TH
    Nat Rev Endocrinol; 2013 Aug; 9(8):479-93. PubMed ID: 23797822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic and cardiovascular risk factors in Klinefelter syndrome.
    Spaziani M; Radicioni AF
    Am J Med Genet C Semin Med Genet; 2020 Jun; 184(2):334-343. PubMed ID: 32452627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Testosterone and the metabolic syndrome].
    Schubert M; Jockenhövel F
    Urologe A; 2010 Jan; 49(1):47-50. PubMed ID: 20063085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone in obesity, metabolic syndrome and type 2 diabetes.
    Stanworth R; Jones T
    Front Horm Res; 2009; 37():74-90. PubMed ID: 19011290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review.
    Saad F; Aversa A; Isidori AM; Gooren LJ
    Curr Diabetes Rev; 2012 Mar; 8(2):131-43. PubMed ID: 22268394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EMAS position statement: Testosterone replacement therapy in the aging male‏.
    Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
    Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sperm Count and Hypogonadism as Markers of General Male Health.
    Ferlin A; Garolla A; Ghezzi M; Selice R; Palego P; Caretta N; Di Mambro A; Valente U; De Rocco Ponce M; Dipresa S; Sartori L; Plebani M; Foresta C
    Eur Urol Focus; 2021 Jan; 7(1):205-213. PubMed ID: 31427194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.